Tumor-associated macrophages (TAMs) are essential components of the cancer microenvironment and play critical roles in the regulation of tumor progression. Optimal therapeutic intervention requires in-depth understanding of the sources that sustain macrophages in malignant tissues. In this study, we investigated the ontogeny of TAMs in murine pancreatic ductal adenocarcinoma (PDAC) models. We identified both inflammatory monocytes and tissue-resident macrophages as sources of TAMs. Unexpectedly, significant portions of pancreas-resident macrophages originate during embryonic development and expand through in situ proliferation during tumor progression. While monocyte-derived TAMs play more potent roles in antigen presentation, embryonically derived TAMs exhibit a pro-fibrotic transcriptional profile, indicative of their role in producing and remodeling extracellular matrix molecules. Collectively, these findings uncover the heterogeneity of TAM origin and functions, and could provide therapeutic insight for PDAC treatment.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignant diseases.
Current therapeutic interventions are extremely ineffective in PDAC treatment, partly due to components in the microenvironment that promote tumor growth. Two hallmarks of the PDAC microenvironment are the dense fibrotic stroma and extensive infiltration of myeloid cells, including macrophages. Tumor-associated macrophages (TAMs) are one of the most abundant immune cells infiltrating PDAC. TAMs promote tumor growth by releasing growth factors, inhibiting anti-tumor adaptive immune responses, modifying angiogenesis, and promoting fibrosis, among other mechanisms (Biswas and Mantovani, 2010; Noy and Pollard, 2014; Ruffell and Coussens, 2015) .
Therefore, high numbers of TAMs correlate with poor patient outcome (Balaz et al., 2002; Ino et al., 2013; Kurahara et al., 2011) . Consequently, TAMs are considered a highly desirable therapeutic target (Mantovani et al., 2014; Noy and Pollard, 2014) .
Optimal therapeutic strategies targeting TAMs require an in-depth understanding of their ontogeny and the mechanisms governing their homeostasis. The traditional view holds that tissue macrophages are derived from circulating Ly6C
Hi monocytes. In the last few years, an increasing amount of evidence suggests that various types of tissue-resident macrophages are established during embryonic development, persist into adulthood, and self-maintain independently of the adult hematopoietic system (Epelman et al., 2014; Ginhoux and Guilliams, 2016; Gomez Perdiguero et al., 2015; Hashimoto et al., 2013; Perdiguero and Geissmann, 2016; Schulz et al., 2012; Varol et al., 2015; Yona et al., 2013) . Under homeostatic conditions, macrophages derived from different developmental origins co-exist in many organs. Two notable exceptions are brain microglia, the majority of which are generated during embryonic hematopoiesis at the yolk sac stage (Ginhoux et al., 2010; Hoeffel et al., 2015) , and intestinal macrophages, which rely on continuous replenishment by adult blood monocytes (Bain et al., 2014) . Macrophages in many other organs, including the pancreas, have mixed origins (Calderon et al., 2015) . A limited number of studies suggest that coexisting macrophages, derived from different developmental origins, have both overlapping and distinct functions within the same tissue (Epelman et al., 2014; Gibbings et al., 2015) . However, more studies are needed to address the correlation between the ontogeny and functionality of different macrophage subsets.
Despite the growing body of knowledge of tissue-resident macrophages, monocytes are still often considered as the precursors of macrophages in tumors (Franklin and Li, 2016) . Indeed, multiple studies in several tumor models have demonstrated the contribution of circulating monocytes to sustaining TAM numbers. (Franklin et al., 2014; Laoui et al., 2014; Movahedi et al., 2010b) . In addition to bone marrow, spleen was also shown to serve as an extramedullary hematopoietic site that supplies monocytes to replenish TAM pools (Cortez-Retamozo et al., 2013) . However, the contribution of tissue-resident macrophages to TAMs has largely been understudied. Tissue-resident macrophages are known to proliferate in situ under pathological conditions (Amano et al., 2014; Jenkins et al., 2011) . In addition, in situ proliferating macrophages have been observed in human cancers (Campbell et al., 2010) . However, it is not known whether proliferation of tissue-resident macrophages contributes to TAM numbers in malignancies.
In this study, we document a previously unappreciated heterogeneity in the ontogeny of TAMs in pancreatic ductal adenocarcinoma. We identify both Ly6C Hi monocytes and tissue-resident macrophages of embryonic origin as sources of TAMs. More importantly, TAMs derived from different origins demonstrate distinct phenotypes and transcriptional profiles, suggesting divergent functionality.
While monocyte-derived TAMs are more potent at sampling tumor antigens and regulating adaptive immune responses, embryonically derived TAMs have higher expression levels of pro-fibrotic genes that encode for extracellular matrix (ECM) and ECM remodeling molecules. These data reveal a potential novel function of embryonically derived macrophages, and suggest a previously unknown interaction between TAMs and the fibrotic PDAC stroma, which could serve as a therapeutic target for PDAC treatment.
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RESULTS
Pancreatic Ductal Adenocarcinoma Tissues are Infiltrated with Macrophages
High levels of fibrosis and extensive inflammatory cell infiltration characterize the tumor microenvironment of human PDAC. Among the infiltrating cells, macrophages are frequently a dominant component. This can be readily observed by comparing the expression of panmacrophage/myeloid cell markers CD68, CD163, and CD206 in paired human pancreatic tissue samples containing both PDAC lesions and adjacent normal tissue ( Figure 1A-B) . This increase in macrophage number parallels the levels of tissue fibrosis. While tumor infiltration by macrophages is well characterized, the sources of these macrophages have not been elucidated completely.
To explore the ontogeny of TAMs in PDAC, we analyzed p48-Cre + /LSL-Kras G12D /p53 flox/+ (KPC) genetically engineered mouse models (GEMMs), which undergo stepwise progression through stages of pancreatic intraepithelial neoplasia (PanIN) and ultimately develop PDAC (Hingorani et al., 2005 ). The KPC model faithfully recapitulates many pathological features of the human disease, including progressive development of stromal fibrosis and extensive accumulation of macrophages Figure 1D ), and syngeneic orthotopic PDAC tumors established using KPC-derived cancer cell lines (KPC-1) ( Figure S1 ). In all cases, we confirmed macrophage identity in our gating strategy based on the expression of CD68, MerTK, CD64 (Gautier et al., 2012) , colony-stimulating factor-1 receptor (CSF1R), and CX3C chemokine receptor-1 (CX3CR1), but not Siglec-F ( Figure 1E , S1C). To confirm the exclusion of dendritic cells (DCs) in our macrophage gating, we established orthotopic tumors in Zbtb46 gfp/+ reporter mice (Satpathy et al., 2012) , and found minimal GFP signal in the macrophage population compared to DC specific gating strategies ( Figure 1E, S1D) . Furthermore, the vast majority of DCs in both normal pancreas and orthotopic PDAC (identified by CD45 + Zbtb46-GFP + ) express considerably lower levels of macrophage markers, including MerTK, CD64, F4/80, and CX3CR1 ( Figure S1E ), suggesting that pancreas-infiltrating macrophages are phenotypically distinct from DCs. Flow cytometry analyses of tissues from the KPC mouse model demonstrated a 24-fold increase in total number and 5-fold increase in density of macrophages in end-point PDAC compared to normal pancreas ( Figure 1F) . Similarly, macrophage numbers expand in orthotopic PDAC tissues as the tumors progress ( Figure 1G ). Taken together, the dramatic upregulation of the number and density of macrophages in KPC mouse models mimics that seen in human pancreatic cancer. However, the sources of these macrophages are not clearly defined.
(Figure 1C
)
Subsets of Macrophages in Pancreas and PDAC Tissues Are Maintained Independently of Blood Monocytes
To test the contribution of blood monocytes to macrophages in tumors, we first performed parabiosis by surgically joining the CD45.2-expressing KPC mice with congenic wild-type mice that express CD45.1. Parabiotic pairs were set up when KPC mice were 3.5 months of age. At this age, KPC mice have developed extensive PanIN lesions, with microscopic evidence of progression to full PDAC. To study the contribution of blood monocytes to macrophages in PDAC, we analyzed chimerism after 6 weeks (at 5 months of age), when disease in KPC mice would have progressed to late-stage PDAC. We also evaluated chimerism in a cohort of mice 2 weeks after the establishment of parabiosis to study the dynamics of macrophage turnover. We observed 28% chimerism of Ly6C
Hi monocytes in the blood of KPC mice within the first 2 weeks, which did not increase further after 6 weeks of parabiosis (Figures 2A-2B ). This level of chimerism was mirrored by tissue-infiltrating
Ly6C
Hi monocytes in both normal pancreas and KPC tumors ( Figure S2A-B) . However, tissue macrophages in steady-state pancreas only achieved 2.5% chimerism after 6 weeks of parabiosis (Figures 2B), suggesting that the majority of macrophages are maintained independently of circulating monocytes during this time period. This level of chimerism was close to what we observed in brain microglia (0.5%), which are known to be locally maintained (Ginhoux et al., 2010; Hoeffel et al., 2015) . Interestingly, the chimerism of macrophages present in KPC tumors was only 8.8%, compared to 27% for Ly6C Hi monocytes in the same tissue. These data suggest that while monocytes contribute to the expansion of macrophage numbers during PDAC progression, they might not be the sole source of macrophages in tumor tissues. Additionally, the level of chimerism observed in macrophages in PDAC tissues was comparable after 2 and 6 weeks, in spite of significant increases in macrophage numbers during this time period ( Figure 2B ). These data suggest that chimerism reached equilibrium within 2 weeks of parabiosis and that the expansion of TAMs was maintained with equal contributions from both monocytes and other sources.
It is well appreciated that macrophages in tumors exist in subsets with distinct pro-tumor activities. One approach to identity these TAM subsets is based on differential expression of major histocompatibility class (MHC) II (denoted MHCII Hi and MHCII Low here-in) (Movahedi et al., 2010a; Zhu et al., 2014) . To determine if monocytes replenish these subsets differentially, we analyzed the tumor tissue following parabiosis. We found that the MHCII Hi subset constituted up to 80% of the donor-derived TAMs, suggesting that monocytes preferentially, but not exclusively, replenish this population over the 6-week time course ( Figure 2C ).
To complement these parabiosis studies, we established bone marrow chimeras by lethally irradiating wild-type CD45.2 + mice and adoptively transferring bone marrow cells from CD45.1 + wildtype mice. Six weeks after transfer, more than 99% of the immune cells in the blood and the bone marrow of KPC mice were CD45.1 + donor-derived ( Figure 2D ). Strikingly, despite potential elimination of radio-sensitive tissue-resident macrophages and the influx of Ly6C Hi monocytes induced by irradiation, 30% of macrophages in the pancreas were host-derived (CD45.2 + ) ( Figure   2D ). In parallel, we lethally irradiated 3.5-month-old KPC mice at the PanIN stage, adoptively transferred bone marrow cells from CD45.1 + wild-type mice, and analyzed chimerism 6 weeks later in fully established PDAC. Similarly, a significant portion (>15%) of TAMs in KPC tumors were hostderived, which contrasts with the >99% chimerism detected in circulating monocytes ( Figure 2G ).
These data confirmed the existence of pancreas-resident TAMs that were not rapidly replaced by blood monocytes. Consistent with the results of the parabiosis studies, host-derived (CD45.2 + ) macrophages were preferentially, but not exclusively, MHCII Low in both normal pancreas and KPC tumor tissues ( Figures 2E-F, 2H ).
To further assess the short-term contribution of blood monocytes to TAM maintenance, we 
Impairment of Circulating Monocytes Alone Does Not Impact PDAC Progression
To determine the long-term contribution of blood monocytes to macrophages in the pancreas, we evaluated pancreas and PDAC macrophages in CCR2-and Nur77-defficient mice, which have impairments in circulating Ly6C Hi and Ly6C Low monocytes, respectively (Hanna et al., 2011; Serbina and Pamer, 2006) . Despite >95% reduction in the number of circulating Ly6C hi monocytes ( Figures   3A and S3A) , the frequency of macrophages in steady-state pancreas was not changed in CCR2-deficient mice ( Figure S3B ). Additionally, while in PDAC tumor-bearing CCR2 -/-mice, circulating
Ly6C
Hi monocytes was still decreased by >95%, PDAC-infiltrating macrophages were decreased by only 50% (Figures 3B and S3C) . Consistent with the results of the monocyte labeling experiments, CCR2 deficiency decreased MHCII Hi TAM frequency, while MHCII Low TAMs were not affected ( Figure   3C ). Surprisingly, while CCR2 deficiency did reduce macrophage numbers, this did not impact tumor growth in two independent PDAC models ( Figures 3D and S3D ). Similar to these syngeneic PDAC models, there were no changes in tumor burden in KPPC GEMMs treated with CCR2 inhibitors continuously for 45 days ( Figure 3K ).
To address the possibility that Ly6C Low monocytes might contribute to macrophages in PDAC tissues, we analyzed Nur77 -/-mice. Similar to data from a previous reports (Hanna et al., 2011) Figures 3H and S4E) . Together, these data suggest that circulating Ly6C
Hi monocytes are important for sustaining MHCII Hi macrophages, but dispensable for tumor progression.
Tissue-Resident Macrophages Promote PDAC Progression
To determine whether tissue-resident macrophages regulate tumor growth, we treated tumornaïve mice with CSF1 neutralizing antibodies in combination with clodronate-loaded liposomes, followed by a 10-day chase period to allow mice to recover circulating monocyte numbers. Following the 10-day recovery, we found that circulating monocyte numbers in αCSF1/clodronate-treated animals were restored to control/untreated levels ( Figure 3I ). By contrast, pancreas-resident macrophages were depleted as early as 12 hours after injection and remained depleted by 85-95% after 10 days of recovery ( Figures 3I and S3F ). These data suggest that this regimen could allow us to test the impact of the loss of tissue-resident macrophages without decreasing circulating inflammatory monocyte numbers. To study how loss of resident macrophages affects tumor progression, we established orthotopic PDAC tumors 10 days after treatment with αCSF1/clodronate or IgG/PBS. We found that loss of resident macrophages prior to tumor implantation resulted in a 50% reduction in TAMs in established tumors ( Figures 3I and S3F ). These data suggest that loss of resident macrophages is not fully compensated for by monocyte-derived TAMs. In contrast to observations in CCR2-null mice, depletion of pancreas-resident macrophages led to a significant reduction in tumor burden, as measured by both bioluminescence imaging (BLI) and tumor wetweights ( Figure 3J ). These studies were repeated using two distinct KPC-derived PDAC models ( Figure S3G ). To exclude the possibility that the impaired tumor progression was due to deficient tumor "seeding" upon implantation, we treated two genetic PDAC models (KPC and KPPC mice) with (Figures 3L-M) . Taken together, these data suggest that pancreas-resident macrophages are more critical, compared to monocyte-derived TAMs, in driving PDAC tumor progression.
Embryonically Derived Macrophages are Significant Components of Tissue-Resident
Macrophages and Expand During Tumor Progression
To determine whether tissue-resident macrophages are derived from the adult hematopoietic system, we performed lineage tracing using Flt3-Cre
Flt3 is upregulated at the multipotent progenitor stages of hematopoietic stem cell (HSC) differentiation (Boyer et al., 2011) . HSC-derived cells that have gone through the Flt3 + stage become labeled as YFP-positive, whereas macrophages derived from embryonic progenitors outside HSCs are YFP-negative (Schulz et al., 2012) . To validate this model, we analyzed circulating leukocytes and found that >95.5% of leukocytes in the blood, including both Ly6C Hi and Ly6C Low monocytes, were YFP-positive in both steady-state and tumor-bearing mice ( Figure 4A ). As controls, we analyzed colon macrophages and brain microglia. Consistent with previous reports (Bain et al., 2014; Ginhoux et al., 2010) , in adult mice (8-10 weeks old), 93% of the macrophages in the colon were YFP-positive and 98.8% of brain microglia were YFP-negative ( Figure 4B ). In contrast, we observed heterogeneity of macrophage ontogeny in pancreatic tissues, with 32.4% of tissue macrophages labeled as YFP-negative. To determine if this heterogeneity is retained in aged mice, we analyzed 15-month-old Flt3-Cre YFP reporter mice and found that 30% of the macrophages in the pancreas were still YFP-negative ( Figures S4A-B) . These data suggest that embryonically derived pancreasresident macrophages persist with age.
To determine whether these YFP-negative macrophages persist during tumor progression, we The presence of large numbers of YFP-negative macrophages suggests that many TAMs could be derived during embryonic hematopoiesis. Alternatively, these cells could have originated from adult HSCs without going through extensive Flt3 + stages. To distinguish between these two possibilities, we treated Flt3-Cre YFP mice with one dose of a CSF1R antibody (αCSF1R) at 13.5 days post coitum (E13.5) (Hoeffel et al., 2015) to deplete macrophages derived from embryonic sources.
We then quantified the abundance of YFP-negative macrophages in the pancreas of F1 progenies as they reached 6 weeks of age. Treatment with αCSF1R on embryonic day E13.5 resulted in 80% reduction in the density of YFP-negative macrophages in steady-state pancreas ( Figure 4G ). To further confirm the contribution of embryonically derived macrophages to TAMs in PDAC, we orthotopically implanted KPC tumor cells in adult mice following αCSF1R treatment on E13.5.
Embryonic αCSF1R treatment resulted in a 40-60% reduction in the number of macrophages in established tumors ( Figure 4H ). Additionally, the loss of embryonically derived macrophages led to delayed tumor progression in two distinct syngeneic PDAC models ( Figure 4I ). Taken together these data suggest that embryonically derived macrophages facilitate PDAC progression.
To further assess the specific contribution of embryonic hematopoietic progenitors to PDAC TAMs, we administered one dose of tamoxifen in Csf1r-mer-iCre-mer; Rosa26-LSL-tdTomato mice at E8.5, E9.5, E10.5, E11.5, or E13.5 to span yolk sac and fetal liver stages. Using this model, we observed that HSC-derived circulating monocytes were labeled at all time points later than E9.5
( Figures S5A-B) . Using E8.5 or E9.5 tamoxifen pulsing, we observed labeling in 4% and 10% of macrophages, respectively, in normal pancreas retained the label as mice reached 6 weeks of age labeled with a tamoxifen pulse at E8.5 or E9.5 expanded in number by 6.8-or 13.5-fold, respectively, during PDAC tumor progression (Figures 5C). These data suggest that yolk sac-derived macrophages are a significant source of tissue-resident macrophages that undergo significant numerical expansion during tumor progression.
In both CSF1R-and CX3CR1-driven lineage-tracing models, we observed higher levels of labeling in the MHCII Low macrophage subset ( Figures S5D-E) . Similarly, in the Flt3-Cre reporter mice, significantly larger portions of YFP-negative macrophages constitute the MHCII Low subset in both normal pancreas and PDAC tissues ( Figures S4C-D) . These results further confirm that embryonically derived macrophages are preferentially but not exclusively enriched in the MHCII Low macrophages. Interestingly, we found that in both HSC-derived and embryonically derived TAMs, the MHCII Low subset experiences higher levels of hypoxia. However, macrophage hypoxia level was independent of origin ( Figure S4E-F) . These data suggest that macrophage origin might drive intrinsic differences in macrophage phenotype and function that can be further molded by conditions in the tumor microenvironment.
Embryonically Derived Macrophages Expand through in situ Proliferation
To determine if tissue-resident macrophages undergo expansion through local proliferation, we analyzed Ki67 expression and short-term 5-Bromo-2'-deoxyuridine (BrdU) incorporation in macrophages from normal pancreas and PDAC tissues. Analyses of normal pancreas demonstrated that <1% of macrophages incorporated BrdU following a 3-hour pulse and <3% were Ki67 + ( Figure   6A -D). These data suggest that pancreas-resident macrophages in steady state are mostly quiescent.
On the other hand, >15% of TAMs in either autochthonous KPC PDAC tissues or orthotopic KPC-1 tumors were Ki67 + , and 3.5-4% were labeled with BrdU within 3 hours (Figures 6A-D Figure 6G ). These data suggest that macrophages in PDAC tissues up-regulate proliferative programs, perhaps in response to fibrosis, and that embryonically derived macrophages proliferate at high levels to keep pace with tumor progression.
We next sought to identity what signals sustain the survival of these TAM subsets in PDAC tissues. We took a targeted approach and treated orthotopic PDAC-bearing Flt3-Cre YFP mice with neutralizing antibodies against CSF1 and CSF2, both of which have been implicated in macrophage survival in mouse models of cancer Zhu et al., 2014) . Although CSF2 signal blockade did not change the number of TAMs, inhibition of CSF1 signaling led to a 48% reduction in the YFP-positive and a 75% reduction in the YFP-negative macrophages ( Figure 6H ). These data suggest that CSF1 is important for the survival of both TAM subsets, but embryonically derived macrophages are more sensitive.
Embryonically Derived TAMs Have a Distinct Pro-fibrotic Phenotype.
Having identified both embryonically derived and HSC-derived monocytes as sources of TAMs in PDAC, we next asked whether distinct macrophage origins correlated with phenotypic differences.
Towards that end, we first performed flow cytometry analyses to compare the expression of a panel of cell surface markers in TAM subsets using the Flt3-Cre YFP mice. Both subsets expressed similar levels of macrophage identity markers, including CD64, CD115, and F4/80, whereas YFP-negative
TAMs expressed lower levels of CD11b ( Figures 7A and S7A) , consistent with previous reports of CD11b level in embryonically derived macrophages under homeostatic conditions (Schulz et al., 2012) . YFP-negative TAMs also expressed significantly lower levels of MHCI and MHCII ( Figure 7A ).
Similar differences were also seen between the two macrophage subsets in normal pancreas ( Figure   S7B ), which suggests possibly inherent differences in antigen presentation activities. By contrast, costimulatory molecules (CD80, CD86), T cell-activating molecules (CD40), and immune checkpoint molecules (PDL1, PDL2, PD1) were expressed at comparable levels ( Figure 7A ). Embryonically derived TAMs also expressed significantly higher levels of CX3CR1 and lower levels of CD11a and CD49d ( Figures 7A and S7C) . Interestingly, despite the lack of CXCR4 expression in either macrophage subset in the normal pancreas, CXCR4 was significantly upregulated in TAMs, but only in the YFP-negative population ( Figure 7A and S7B). Taken together, these data suggest that TAMs derived from different origins are phenotypically distinct.
To gain further insight into potential functional differences between embryonically derived and HSC-derived macrophages, we performed transcriptional profiling on macrophages sorted from Flt3-Cre YFP mice (Figures 7B and S7D) . Only a modest number of genes were expressed differentially between the YFP-positive and YFP-negative macrophages in steady-state pancreas tissue. However, 660 genes were differentially expressed (>1.5 fold, p<0.05) between the two subsets in orthotopic KPC tumors, suggesting that TAMs of different origins may have distinct functions in PDAC tumors.
Using gene set enrichment analysis, we found that the genes enriched in embryonic-derived macrophages showed a strong trend toward poor survival when mapped to data sets from human PDAC patients ( Figure S7E) . Analysis of gene ontogeny demonstrated that embryonically derived macrophages had a higher expression of molecules involved in extracellular matrix (ECM) deposition and/or remodeling ( Figure 7C ). Indeed, molecules on top of the list of genes that were expressed at higher levels in embryonically derived TAMs were mostly involved in ECM organization (Table S1 ).
This included genes encoding for ECM molecules (collagen isoforms, nidogen, tenascin C, and elastin), ECM-producing enzymes (hyaluronan synthases 2 and 3), and ECM-remodeling molecules (lysyl oxidase), which we validated using Q-PCR analyses in two independent experiments ( Figures   7D and S7F ). To test if the expression of pro-fibrotic genes is related to functional differences in ECM production, we isolated YFP-positive and YFP-negative TAMs from Flt3-Cre YFP mice and tested their ability to produce collagen ex vivo. Correlating with their differential expression profiles, we found that embryonically derived TAMs could produce significantly more Collagen I and IV ( Figure 7F ). To correlate these ex vivo results to in vivo impact, we analyzed collagen density in PDAC tissue from mice treated on E13.5 with αCSF1R or control IgGs and compared these results to CCR2-deficient mice. We found embryonic macrophage depletion led to reduced collagen deposition. By contrast, CCR2-deficient mice had slightly elevated collagen levels compared to control mice ( Figure S7G ).
These data suggest that macrophages of different origins have differential impacts on fibrosis.
To rule out the possibility that the identified YFP-negative cells contained fibroblasts instead of macrophages, we compared cancer-associated fibroblasts (CAFs) to YFP-negative TAMs. We found that CAFs expressed platelet-derived growth factor receptor-a (PDGFRa), but not CD45, F4/80, or CD11b, whereas YFP-negative TAMs demonstrated the opposite pattern ( Figure S7H) . Similarly, the mRNA expression levels of macrophage/myeloid identity genes (Emr1, Itgam, Csf1r, Csf2r, and Cx3cr1) were comparable in both YFP-positive and YFP-negative TAMs, as determined by Q-PCR analysis, and were 10-to 1000-fold higher in both subsets of TAMs as compared to CAFs ( Figure   S7I ). These data confirm that the YFP-negative cells were not fibroblasts but were a macrophage subset with a unique pro-fibrotic phenotype. To evaluate how the pro-fibrotic gene signature in embryonically derived TAMs differed from that in CAFs, we compared selected fibrosis genes by Q-PCR. As expected, CAFs were the dominant producers of several isoforms of collagens (such as Col1a2 and Col3a1), Elastin, and Sparc ( Figure S7J ). However, mRNA for other ECM molecules, such as Col6a1, Nidogen, and Adamts12, were expressed at comparable levels. In contrast, embryonically derived TAMs were the more dominant expressers of Col4a4, Col10a1, Col17a1, Col18a1, and Has3 ( Figure S7J ). Taken together, these data suggest that embryonically derived
TAMs may be more involved in "fine-tuning" fibrotic responses in PDAC tumors.
In contrast to pro-fibrotic genes, the levels of mRNA involved in class I and class II antigen presentations (Erap1, Psme1, and Ciita) were higher in HSC-derived TAMs ( Figure 7E ). To test the antigen uptake capacity in TAMs subsets in vivo, we orthotopically implanted mCherry + KPC-1 PDAC cells and determined the mCherry positivity in TAMs. Although both TAM subsets demonstrated potent capacity to uptake tumor antigen, the amount of antigen uptake was >2-fold higher in HSCderived TAMs compared to their embryonic counterparts ( Figure 7G ). We next tested the ability of each TAM subset to present antigen (ovalbumin) to OT1 + CD8 + T cells and found that HSC-derived (YFP+) TAMs were far more potent at antigen presentation compared to their embryonically derived (YFP-) counterparts. In addition, HSC-derived TAMs expressed significantly higher levels of Il12a, Il4, Ccl17, and Ifnb1 compared to their embryonic counterparts ( Figure 7E ). Taken together, these data suggest that TAMs derived from HSCs and embryonic sources likely play more potent roles in regulating adaptive immunity and/or driving immune tolerance. This is consistent with previous
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reports showing that monocyte-derived TAMs regulate immunosuppression in PDAC models (Beatty et al., 2015; Mitchem et al., 2013; Sanford et al., 2013) and in early phase clinical trials .
Subsets of TAMs in Human PDAC Tissue Resemble Murine Embryonically Derived TAMs
To address whether the identification and characterization of embryonic TAMs in murine PDAC models is relevant for human cancer, we took advantage of the observation that CXCR4 was almost exclusively upregulated in murine embryonic TAMs ( Figure 7A ). We first evaluated human PDAC tissues for CXCR4 + TAMs and found that 10-40% of TAMs expressed high levels of CXCR4 ( Figure   7I ). We also noted that these CXCR4 + TAMs expressed lower levels of HLA-DR in eight out of nine patients evaluated ( Figure 7J) . These results are consistent with our observation that CXCR4 + TAMs of embryonic origin expressed lower levels of MHCII in murine PDAC models. To determine if this subset of human PDAC TAMs shared the pro-fibrotic gene expression profile we identified in mice, we isolated CXCR4-positive and negative TAMs from PDAC tissues from three untreated surgical patients and performed Q-PCR analyses. Consistent with our animal model data, we found that CXCR4 + TAMs expressed significantly higher levels of Collagens and ECM-modulating molecules compared to their CXCR4-negative counterparts ( Figure 7K ). Collectively, these data suggest that CXCR4 + TAMs in human PDAC resemble the ECM regulatory phenotype of murine embryonically derived PDAC TAMs.
DISCUSSION
Ontological origins of tissue macrophages vary among different tissues under steady state.
With the exception of brain and intestine, many other organs contain macrophages of different origins co-existing within the tissue context. Consistent with previous reports (Calderon et al., 2015) , our study demonstrated that pancreas-associated macrophages contain cells derived from both adult HSCs and embryonic hematopoietic sources. The precise nature of embryonic hematopoietic progenitors that gave rise to these macrophages needs to be defined; likely sources include yolk sacderived erythro-myeloid progenitors (EMPs) (Gomez Perdiguero et al., 2015) and EMP-derived fetal monocytes (Hoeffel et al., 2015) . The origin of HSC-derived macrophages in normal pancreas is also unclear; possible sources include fetal liver HSCs and bone marrow HSC-derived monocytes that may populate the pancreas perinatally. Regardless of developmental origin, significant portions of macrophages in the pancreatic stroma are likely resident in the tissue without rapid replenishment from circulating monocytes. The majority of pancreas-resident macrophages are quiescent under steady state, suggesting that these cells may self-maintain through longevity. It is also important to note that the ontogeny of tissue-resident macrophages is not static. Embryonically derived macrophages in multiple organs have shown various degrees of replacement by monocytes with different kinetics (Bain et al., 2016; Ginhoux and Guilliams, 2016; Molawi et al., 2014) . Our study using aged mice demonstrated that embryonically derived macrophages could persist long-term in the pancreas, despite potential slow replacement by blood monocytes that we cannot rule out. It remains to be seen if and to what extent could embryonically derived macrophages persist in aged human patients.
Fates of tissue-resident macrophages vary under different pathological conditions. For example, liver resident Kupffer cells undergo necroptosis during Listeria monocytogenes infection, which recruits monocytes to replenish macrophages (Bleriot et al., 2015) . On the other hand, tissue macrophages undergo in situ proliferation during helminth infections (Jenkins et al., 2011) . Very few studies have looked at the fate of tissue-resident macrophages during cancer progression. One report documented a loss of resident macrophages concomitant with the increase in monocyte-derived TAMs in a breast cancer model (Franklin et al., 2014) . On the other hand, microglia were shown to be present in brain tumor models (Bowman et al., 2016; Hambardzumyan et al., 2016) . Here, we demonstrated that in PDAC, embryonically derived tissue-resident macrophages not only persisted in the tissue, but also underwent significant proliferative expansion to keep pace with tumor progression.
TAMs in the PDAC tissues adopted a transcriptional program to enhance proliferation, and embryonically derived tissue-resident macrophages further enhanced their proliferative programs compared to the monocyte-derived counterparts. Of note, PDAC also upregulated the proliferation of monocyte-derived macrophages, similar to what is seen in other cancers and tissue repair (Franklin et al., 2014; Wang and Kubes, 2016) ; though their proliferative activities were less robust than those in the embryonically derived macrophages. Factors that sustain and promote in situ proliferation in different TAM subsets, as well as the cellular sources of these factors, have yet to be identified. It also remains to been seen to what extent would these observations hold true in other tumors or if this feature is enriched in PDAC due to its uniquely fibrotic nature. One tumor type of interest is pancreatic neuroendocrine tumors (PNET), which originate from the islets of Langerhans. Under steady state, macrophages in the pancreatic islets are maintained by blood monocytes, whereas stromal macrophages are embryonically derived and locally maintained (Calderon et al., 2015) . It would be interestingly to see whether PNET contrasts with PDAC and relies on circulating monocytes to sustain TAMs in-spite of residing in the same tissue. Answers to these questions could provide insights into how we can therapeutically target TAM subset-specific pathways in order to restrain the progression of different types of tumors even within the same organ.
A highly debated question regarding macrophage ontogeny is the functional differences between macrophages derived from distinct origins that are located within the same tissue context.
This question remains largely unsolved. A limited number of transcriptional studies suggest that
macrophages of different ontogeny demonstrate mostly overlapping transcriptional profiles within the same tissue, at least in non-disease settings (Gibbings et al., 2015; Gundra et al., 2014; van de Laar et al., 2016) . Upon engraftment, circulating monocytes could also replenish the resident macrophage pool and adopt a transcriptional profile similar to their embryonically derived counterparts (Scott et al., 2016) . These studies led to the assumption that tissue environment, as opposed to ontogeny, is the main driver of macrophage functions. Indeed, macrophages resident in different organs or at different niches within the same organ have distinct transcriptional profiles, supporting the concept that tissue environment could educate macrophages to adopt distinct functionalities (Gautier et al., 2012; Mass et al., 2016; Movahedi et al., 2010b; Ojalvo et al., 2009) . However, our microarray data demonstrated that although gene expression profiles of embryonically derived and HSC-derived macrophages are fairly similar in the normal pancreatic tissue, their expression profiles and ex vivo functions are very distinct in PDAC tissues. As a harbinger of this dynamic, CXCR4 is largely not expressed in macrophages of either origin in the normal pancreas, but specifically upregulated in PDAC TAMs of embryonic origin. These data suggest that origin may epigenetically poise macrophages to differentially respond to inflammatory insults with distinct bioactivities, such as ECM modulation or antigen processing/presentation. Future experiments are needed to determine which lineage commitment factors poise macrophages for differing functional responses during tumor progression.
Our studies also demonstrate unique fibrosis-modulating functions in embryonically derived TAMs. Macrophages are well known for their ability to promote fibrosis in multiple physiological and pathological conditions, such as wound healing and cancer (Wynn and Vannella, 2016) . However, such activities are thought to be indirectly executed by activating fibroblasts to lay down and remodel ECM. Here, our data suggest that subsets of macrophages may fine-tune fibrosis by directly depositing and/or remodeling the ECM. Fibrosis is a hallmark of PDAC, which imposes a major physical barrier that not only inhibits endogenous anti-tumor immune responses but also deters effective delivery of chemo-and immune-therapies (Beatty et al., 2011; Jiang et al., 2016) . Although it has been demonstrated that tumor-derived factors promote macrophage expansion and fibrosis, the initiation of these two pathological features were considered to be independent of each other. Our data suggest these responses may be more integrated. Corresponding with this idea, a recent report demonstrated that TAMs directly construct ECM in colon cancer (Afik et al., 2016) . Interestingly, such activities were carried out by monocyte-derived TAMs in their model. Strikingly, depletion of macrophage subsets had different impacts on tumor progression in PDAC models. Loss of monocyte-derived macrophages had limited effects on tumor progression, whereas depletion of tissue-resident macrophages significantly reduced tumor growth and aggressivity/grade. These observations form a nice comparison to several other tumor models, where the depletion of monocyte-derived macrophages inhibits tumor growth and metastasis (Afik et al., 2016; Franklin et al., 2014; Qian et al., 2011) . Although we cannot rule out the importance of monocyte-derived TAMs in the regulation of PDAC development, our data suggest that tissueresident macrophages are important in PDAC progression.
In summary, our study demonstrates that PDAC contains macrophages with heterogeneous ontological origins. In addition to Ly6C Hi monocytes, tissue-resident macrophages derived from 25 embryonic origin are also a major source of TAMs in murine models. Embryonically derived macrophages expand in PDAC tissues through in situ proliferation and exhibit a pro-fibrotic transcriptional profile, suggesting a potential role in fine-tuning fibrosis in PDAC. We provide a new paradigm of macrophage heterogeneity under the tumor setting, which may facilitate future investigations that ultimately improve therapeutics to target the "fibro-inflammatory" microenvironment of PDAC and potentially other cancers.
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EXPERIMENTAL PROCEDURES
Murine PDAC Models KPC mice (p48-CRE/Lox-stop-Lox(LSL)-Kras G12D /p53 flox/+ ) used in these studies have been previously described (Hingorani et al., 2005) and were backcrossed to C57BL/6 background and screened for C57BL/6 identity using congenic markers. KPC-1 cell line was derived from PDAC tissues of 2.2-month-old p48-CRE + /LSL-Lox Kras G12D /p53 flox/flox (KPPC); the KPC-2 cell line was derived from tumors of 6-month-old p48-CRE + /LSL-Lox Kras G12D /p53 flox/+ (KPC) mice. Cells were grown on collagen-coated tissue culture flasks for <12 passages, and were tested for cytokeratin-19, smooth muscle actin, vimentin, and CD45 to verify their carcinoma identity and purity. To establish orthotopic KPC models, either 50,000 or 200,000 KPC-1 or KPC-2 cells in 50 µL of Cultrex (Trevigen) were injected into the pancreas of 6-12-week-old C57BL/6 mice according to published protocol (Kim et al., 2009 were selected by FACS prior to orthotopic implantation.
Labeling of Blood Ly6C hi Monocytes
To selectively label Ly6C hi monocytes, 250 uL of liposomes containing clodronate were injected intraveneously (i.v.), followed by i.v. injection of 250 uL of FITC-conjugated plain microspheres 16-18 hours later (1.0 um, 2.5% solids [wt/vol]; Polysciences, diluted 1:4 in PBS). Tissues were processed for flow cytometry analyses at indicated time points after bead injection.
Macrophage Depletion
To deplete tissue resident macrophages, 8-16-week old C57BL/6 mice were treated with 3 doses of CSF1 neutralizing antibody (clone 5A1, BioXCell) (1 mg, 0.5 mg, 0.5 mg on Days -18, -14, and -11, Similarly, KPC and KPPC mice were treated with 2 doses of αCSF1 (0.5 mg each, Day 1 and Day 5) and 2 doses of clodronate-loaded liposome (100 uL each, Day 3 and Day 7) starting at 2.5-month and 1-month of age, respectively. Tumor burden was analyzed when mice reached 4.5 months for KPC mice or 2.0 months for KPPC mice.
To deplete embryonically derived macrophages, C57BL/6 or Flt3-Cre YFP mice were intraperitoneally injected with 3.0 mgs of CSF1R depleting antibody (AFS98 clone, BioXCell) on 13.5 dpc. Surviving mice were implanted with 50,000 CBR + KPC-1 at 6 weeks of age. Mice were sacrificed 12 days after tumor establishment for flow cytometry and tumor burden analyses.
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